Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: AMPK activators - Ligand Pharmaceuticals/Merck

Drug Profile

Research programme: AMPK activators - Ligand Pharmaceuticals/Merck

Alternative Names: MB 07562

Latest Information Update: 29 Mar 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Metabasis Therapeutics
  • Developer Ligand Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Diabetes mellitus; Hyperlipidaemia

Most Recent Events

  • 29 Jan 2010 Metabasis Therapeutics has been acquired by Ligand Pharmaceuticals
  • 11 Jun 2009 Merck selects a lead candidate for late preclinical development under its 4-year research collaboration agreement with Metabasis
  • 24 Apr 2008 Metabasis and Merck extend their collaboration for AMPK aktivators for diabetes and other metabolic diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top